KC-2054

CT26-PVR Cell Line

44930

Home » CT26-PVR Cell Line

Background of CT26-PVR Cell Line

The poliovirus receptor PVR, also known as CD155 or NECL-5. PVR mediates natural killer cell adhesion and triggers its effector function, participates in mediating tumor cell infiltration and migration, and is the attachment receptor of poliovirus. PVR is expressed in monocytes, macrophages, thymocytes and neurons of the central nervous system. PVR is able to bind CD226, DNAX accessory molecule-1 (DNAM-1), T Cell-Activated Increased Late Expression Protein, TACTILE (CD96), and T Cell Immunoreceptor with Ig and ITIM domains (TIGIT). PVR expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma. Nectin Therapeutics is developing a CD155 antibody, NTX-1088, in clinical phase.

Specifications

Catalog Number	KC-2054
Cell Line Name	CT26-PVR Cell Line
Host Cell Line	CT26
Description	Stable CT26 cell line expressing exogenous human PVR gene
Quantity	Two vials of frozen cells (≥2-10⁶/vial)
Stability	Stable in culture over a minimum of 10 passages
Application	Drug screening and biological assays
Freezing Medium	70% DMEM + 20% FBS + 10% DMSO
Propagation Medium	DMEM + 10% FBS + 10ug/ml Puromycin
Selection Marker	Puromycin
Morphology	Fibroblastoid cells growing as a monolayer
Subculture	Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 10⁵ cells/ml
Incubation	37 °C with 5% CO₂
Storage	Liquid nitrogen immediately upon receiving
Doubling Time	Approximately 30 hours
Mycoplasma Status	Negative
In Vivo Validation	NA

Cell Line Generation

CT26 PVR cell line was generated using a lentiviral vector expressing the human PVR sequence.

Characterization

Figure: Characterization of PVR overexpression in CT26 stable clones using FACS.

Cell Resuscitation

1. Prewarm culture medium (RPMI1640 supplemented with 10% FBS and 10μg/mL Puromycin)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO₂ incubator.
8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 10⁵ cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI1640 + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3 x106 cells/ml in chilled freezing medium.
6. Aliquot 1 ml of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a −80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1.CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis.Jin AL, et al. Clin Transl Med, 2022 Apr. PMID 35384345.
2.Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.Yoshikawa K, et al. PLoS One, 2021. PMID 34115802.
3.CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers.Zhang H, et al. Technol Cancer Res Treat, 2021 Jan-Dec. PMID 33576304.